Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options for relapsed MCL are limited, although several single agents have been studied. Lenalidomide is available in Italy for patients with MCL based on a local disposition of the Italian Drug Agency.
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) / Stefoni, Vittorio; Pellegrini, Cinzia; Broccoli, Alessandro; Baldini, Luca; Tani, Monica; Cencini, Emanuele; Figuera, Amalia; Ansuinelli, Michela; Bernocco, Elisa; Cantonetti, Maria; Cox, Maria Christina; Ballerini, Filippo; Rusconi, Chiara; Visco, Carlo; Arcaini, Luca; Fama, Angelo; Marasca, Roberto; Volpetti, Stefano; Castellino, Alessia; Califano, Catello; Cavaliere, Marina; Gini, Guido; Liberati, Anna Marina; Musuraca, Gerardo; Lucania, Anna; Ricciuti, Giuseppina; Argnani, Lisa; Zinzani, Pier Luigi. - In: THE ONCOLOGIST. - ISSN 1083-7159. - STAMPA. - 23:9(2018), pp. 1033-1038. [10.1634/theoncologist.2017-0597]
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)
Stefoni, Vittorio;Pellegrini, Cinzia;Broccoli, Alessandro;Tani, Monica;Musuraca, Gerardo;Argnani, Lisa;Zinzani, Pier Luigi
2018
Abstract
Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options for relapsed MCL are limited, although several single agents have been studied. Lenalidomide is available in Italy for patients with MCL based on a local disposition of the Italian Drug Agency.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
